A DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL TRIAL OF VITAMIN-C TREATMENT IN ELDERLY PATIENTS WITH HYPERTENSION

被引:54
作者
GHOSH, SK
EKPO, EB
SHAH, IU
GIRLING, AJ
JENKINS, C
SINCLAIR, AJ
机构
[1] UNIV WALES COLL CARDIFF,CARDIFF ROYAL INFIRM,DEPT GERIATR MED,CARDIFF CF2 1SZ,S GLAM,WALES
[2] WREXHAM MAELOR HOSP,WREXHAM,CLWYD,WALES
[3] UNIV BIRMINGHAM,DEPT MATH & STAT,BIRMINGHAM,W MIDLANDS,ENGLAND
关键词
HYPERTENSION; VITAMIN-C (ASCORBIC ACID); FREE RADICALS; ANTIOXIDANTS;
D O I
10.1159/000213595
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
We have investigated the effect on blood pressure of treatment with vitamin C (an antioxidant and free radical scavenger) in patients with both systolic and essential hypertension. Following a 2-week run-in phase, two age- and sex-matched groups of untreated hypertensive subjects were randomised in a double-blind study to receive 6 weeks' oral treatment with either vitamin C, 250 mg twice daily (n = 22; 8M/14F, mean age 73.7 +/- 4.9 years) or placebo, one capsule twice daily (n = 26; 10M/16F, mean age 73.8 +/- 5.3 years). Blood pressure was measured in the sitting position using a random zero sphygmomanometer on three occasions during the run-in phase, and again at 2, 4 and 6 weeks after commencing treatment. Venous blood samples for measurement of plasma ascorbic acid (AA) and lipid peroxides (LP) were measured in all subjects at baseline and at 4 and 6 weeks after the start of vitamin C or placebo treatment. During the study period, significant falls in both systolic (vitamin C group, mean change -10.3 (95% CI 0.7-20.0) mm Hg, p = 0.05) and diastolic (vitamin C group, mean change -5.9 (95% CI 0.2-11.5) mm Hg, p = 0.03; placebo group, mean change -4.7 (95% CI 0.3-9.1) mm Hg, p = 0.05) blood pressure occurred. However, no statistical difference between the effects of either treatment on blood pressure was observed. At baseline, AA concentrations were lower in the vitamin C-treated group compared with the placebo group (44.6 +/- 2.4 vs. 57.7 +/- 4.2 mu mol/l, p < 0.05). At 6 weeks, AA concentrations were similar to baseline in the placebo group (50.8 +/- 4.6 mu mol/l) but were significantly higher than at baseline in the vitamin C-treated group (80.7 +/- 7.5 mu mol/l, p < 0.001). At baseline, LP concentrations were similar in the vitamin C and placebo-treated groups (5.0 +/- 1.0 vs. 3.6 +/- 0.8 nmol/l, respectively). After 6 weeks' treatment with vitamin C, LP concentrations fell significantly to 1.6 +/- 0.4 nmol/l, but no significant change after placebo was observed (4.4 +/- nmol/l). We conclude: (1) No significant fall in blood pressure occurred after 6 weeks' treatment with vitamin C in comparison with placebo; (2) vitamin C treatment is associated with a marked antioxidant action but further studies are required to relate whether this action is relevant to any hypotensive action of this vitamin; (3) the small fall in systolic blood pressure after vitamin C may have wider implications in population-based studies in reducing stroke incidence in elderly patients and suggests the need for large long-term studies to be established.
引用
收藏
页码:268 / 272
页数:5
相关论文
共 12 条
[1]   VITAMIN-C AND BLOOD-PRESSURE [J].
BULPITT, CJ .
JOURNAL OF HYPERTENSION, 1990, 8 (12) :1071-1075
[2]   RAPID MANUAL METHOD FOR ROUTINE ASSAY OF ASCORBIC-ACID IN SERUM AND PLASMA [J].
DAY, BR ;
WILLIAMS, DR ;
MARSH, CA .
CLINICAL BIOCHEMISTRY, 1979, 12 (01) :22-26
[3]   FREE-RADICALS IN DISEASE PROCESSES - A COMPILATION OF CAUSE AND CONSEQUENCE [J].
GUTTERIDGE, JMC .
FREE RADICAL RESEARCH COMMUNICATIONS, 1993, 19 (03) :141-158
[4]   ARE FREE-RADICALS INVOLVED IN THE PATHOBIOLOGY OF HUMAN ESSENTIAL-HYPERTENSION [J].
KUMAR, KV ;
DAS, UN .
FREE RADICAL RESEARCH COMMUNICATIONS, 1993, 19 (01) :59-66
[5]  
LEGUEN CA, 1992, AGENTS ACTIONS, V36, P264
[6]  
LOVAT LB, 1993, J HUM HYPERTENS, V7, P403
[7]  
PACY PJ, 1987, DIABETES HEART, pCH3
[8]   BLOOD-PRESSURE, DIETARY FATS, AND ANTIOXIDANTS [J].
SALONEN, JT ;
SALONEN, R ;
IHANAINEN, M ;
PARVIAINEN, M ;
SEPPANEN, R ;
KANTOLA, M ;
SEPPANEN, K ;
RAURAMAA, R .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1988, 48 (05) :1226-1232
[9]  
SELWYN AP, 1983, LANCET, V2, P152
[10]  
SINCLAIR AJ, 1990, BRIT J HOSP MED, V43, P334